The grant will help advance the development of a tuberculosis test. Credit: create jobs 51 / Shutterstock.com.

Co-Diagnostics has received an $8.97m grant from the Bill & Melinda Gates Foundation to support a tuberculosis (TB) test that is under development.

This test is designed to run on the forthcoming Co-Dx PCR platform.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company will use this TB test for regulatory and clinical validation activities to increase manufacturing capacity and support further software development for the platform.

Co-Diagnostics will use the funding to leverage the existing infrastructure and manufacturing capabilities of its Indian joint venture, CoSara Diagnostics.

The grant will help improve and extend these assets to meet the expected testing demand when the Co-Dx PCR platform and the associated TB test become available.

The World Health Organization (WHO) highlighted the requirement to significantly boost the accessibility of cost-effective, point-of-care TB diagnostics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This will facilitate quicker treatment decisions for TB, a disease with a roughly 50% mortality rate when untreated.

Co-Diagnostics CEO Dwight Egan said: “Co-Dx is committed to making point-of-care TB diagnostics more accessible around the world and we are pleased that this commitment will be supported by the additional proceeds of this new grant as we follow through on our mission to prevent the spread of infectious diseases by increasing the availability of PCR diagnostics worldwide.

“The WHO estimates that nearly 40% of TB cases went undiagnosed in 2021, or roughly 4.2 million, which represents a significant opportunity for this new platform to make a positive impact.”